Navidea Biopharmaceuticals Announces Positive Initial Results in Single-Center Cohort from Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive I

07-02-2014 Business Wire HealthComments (0)

BiotechnologyNavidea BiopharmaceuticalsNeurologicalPharmaceuticalUSA

Navidea’s NAV4694 agent, produced highly differentiated images in the first cohort of subjects enrolled in the Company’s Phase 2b PET imaging study of subjects with Mild Cognitive Impairment (MCI).

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top